Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ataxia | 7 | 2020 | 77 | 3.910 |
Why?
|
| Fragile X Syndrome | 8 | 2020 | 189 | 3.800 |
Why?
|
| Tremor | 7 | 2020 | 116 | 3.780 |
Why?
|
| Postural Balance | 4 | 2021 | 115 | 1.460 |
Why?
|
| Gait | 6 | 2020 | 391 | 1.370 |
Why?
|
| Fragile X Mental Retardation Protein | 5 | 2016 | 116 | 1.350 |
Why?
|
| Accidental Falls | 3 | 2020 | 110 | 1.350 |
Why?
|
| Gait Disorders, Neurologic | 3 | 2020 | 139 | 1.260 |
Why?
|
| Heterozygote | 4 | 2020 | 92 | 1.190 |
Why?
|
| Walking Speed | 2 | 2020 | 40 | 0.830 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 192 | 0.810 |
Why?
|
| Databases, Factual | 2 | 2021 | 306 | 0.800 |
Why?
|
| Walking | 2 | 2022 | 249 | 0.780 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.700 |
Why?
|
| Nootropic Agents | 1 | 2020 | 12 | 0.690 |
Why?
|
| Attention | 1 | 2020 | 122 | 0.670 |
Why?
|
| Huntington Disease | 1 | 2020 | 48 | 0.660 |
Why?
|
| Movement Disorders | 2 | 2020 | 90 | 0.660 |
Why?
|
| Phenotype | 3 | 2016 | 283 | 0.650 |
Why?
|
| Male | 17 | 2021 | 13545 | 0.650 |
Why?
|
| Female | 16 | 2021 | 13845 | 0.600 |
Why?
|
| Cyclodextrins | 1 | 2018 | 9 | 0.600 |
Why?
|
| Executive Function | 1 | 2018 | 112 | 0.590 |
Why?
|
| Niemann-Pick Disease, Type C | 1 | 2018 | 24 | 0.590 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 902 | 0.580 |
Why?
|
| Humans | 16 | 2022 | 25181 | 0.480 |
Why?
|
| Middle Aged | 9 | 2020 | 8136 | 0.480 |
Why?
|
| Aged | 9 | 2022 | 8400 | 0.470 |
Why?
|
| Receptors, Estrogen | 5 | 1995 | 57 | 0.460 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.450 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 17 | 0.440 |
Why?
|
| Adolescent | 4 | 2021 | 1998 | 0.420 |
Why?
|
| Cognition Disorders | 1 | 2018 | 939 | 0.390 |
Why?
|
| Neuropsychological Tests | 4 | 2020 | 1189 | 0.370 |
Why?
|
| Biomechanical Phenomena | 4 | 2022 | 588 | 0.370 |
Why?
|
| Child | 3 | 2021 | 1232 | 0.360 |
Why?
|
| Reference Values | 2 | 2021 | 185 | 0.360 |
Why?
|
| Walk Test | 2 | 2020 | 9 | 0.350 |
Why?
|
| Adult | 5 | 2021 | 7087 | 0.340 |
Why?
|
| Child, Preschool | 2 | 2021 | 588 | 0.320 |
Why?
|
| Young Adult | 3 | 2021 | 1749 | 0.320 |
Why?
|
| Hippocampus | 4 | 1995 | 247 | 0.310 |
Why?
|
| Cognition | 3 | 2020 | 1263 | 0.260 |
Why?
|
| Parkinson Disease | 3 | 2020 | 818 | 0.250 |
Why?
|
| Shoes | 1 | 2022 | 30 | 0.200 |
Why?
|
| Case-Control Studies | 2 | 2020 | 539 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2020 | 358 | 0.190 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2020 | 4 | 0.180 |
Why?
|
| Retrospective Studies | 2 | 2020 | 3105 | 0.180 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 16 | 0.170 |
Why?
|
| Foot | 1 | 2020 | 31 | 0.170 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 19 | 0.170 |
Why?
|
| Arm | 1 | 2020 | 72 | 0.170 |
Why?
|
| Range of Motion, Articular | 2 | 2020 | 645 | 0.160 |
Why?
|
| Animals | 7 | 2016 | 3378 | 0.150 |
Why?
|
| Mutation | 1 | 2020 | 306 | 0.150 |
Why?
|
| Infusions, Spinal | 1 | 2018 | 6 | 0.150 |
Why?
|
| Spinal Puncture | 1 | 2018 | 24 | 0.150 |
Why?
|
| Motor Activity | 1 | 2020 | 305 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2016 | 4503 | 0.140 |
Why?
|
| Brain Tissue Transplantation | 2 | 1993 | 16 | 0.140 |
Why?
|
| Congresses as Topic | 1 | 2016 | 28 | 0.140 |
Why?
|
| Posture | 1 | 2016 | 63 | 0.130 |
Why?
|
| Time Factors | 1 | 2020 | 1327 | 0.130 |
Why?
|
| Computers | 1 | 2015 | 22 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2015 | 61 | 0.130 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2015 | 45 | 0.130 |
Why?
|
| Neuroimaging | 1 | 2016 | 133 | 0.130 |
Why?
|
| Animals, Newborn | 3 | 1993 | 42 | 0.130 |
Why?
|
| Reaction Time | 1 | 2015 | 107 | 0.130 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 72 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 250 | 0.120 |
Why?
|
| Sexual Behavior, Animal | 1 | 1994 | 1 | 0.120 |
Why?
|
| Cerebral Cortex | 2 | 1993 | 161 | 0.120 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1994 | 11 | 0.120 |
Why?
|
| Pituitary-Adrenal System | 1 | 1994 | 11 | 0.120 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 23 | 0.120 |
Why?
|
| Arousal | 1 | 1994 | 41 | 0.120 |
Why?
|
| Disability Evaluation | 1 | 2016 | 276 | 0.120 |
Why?
|
| RNA, Messenger | 1 | 1995 | 240 | 0.120 |
Why?
|
| Disease Progression | 1 | 2016 | 649 | 0.110 |
Why?
|
| Rats | 6 | 1995 | 598 | 0.110 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 46 | 0.110 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 7 | 0.110 |
Why?
|
| Movement | 1 | 2013 | 109 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 498 | 0.100 |
Why?
|
| Neurons | 2 | 1995 | 287 | 0.100 |
Why?
|
| Treatment Outcome | 1 | 2020 | 3146 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 1113 | 0.090 |
Why?
|
| Cohort Studies | 1 | 2016 | 1757 | 0.090 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 1036 | 0.080 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1995 | 304 | 0.060 |
Why?
|
| Fetal Tissue Transplantation | 2 | 1993 | 21 | 0.050 |
Why?
|
| Estradiol | 2 | 1993 | 36 | 0.050 |
Why?
|
| Mechanical Phenomena | 1 | 2022 | 24 | 0.050 |
Why?
|
| Pregnancy | 2 | 1993 | 303 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 642 | 0.040 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 1995 | 1 | 0.030 |
Why?
|
| N-Methylaspartate | 1 | 1995 | 3 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 1995 | 6 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1995 | 9 | 0.030 |
Why?
|
| Sex Differentiation | 1 | 1995 | 2 | 0.030 |
Why?
|
| Blotting, Northern | 1 | 1995 | 18 | 0.030 |
Why?
|
| DNA, Complementary | 1 | 1995 | 23 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 1995 | 32 | 0.030 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 1994 | 8 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 7 | 0.030 |
Why?
|
| Rats, Inbred Strains | 2 | 1992 | 18 | 0.030 |
Why?
|
| Gene Expression | 1 | 1995 | 176 | 0.030 |
Why?
|
| Cytosol | 2 | 1992 | 55 | 0.030 |
Why?
|
| Transplantation, Heterotopic | 1 | 1993 | 4 | 0.030 |
Why?
|
| Preoptic Area | 1 | 1993 | 6 | 0.030 |
Why?
|
| Brain Mapping | 1 | 1994 | 164 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 832 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 1993 | 74 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 1994 | 232 | 0.030 |
Why?
|
| Age Factors | 1 | 1995 | 720 | 0.030 |
Why?
|
| Aging | 2 | 1993 | 1520 | 0.030 |
Why?
|
| Calcium | 1 | 1995 | 473 | 0.020 |
Why?
|
| Diethylstilbestrol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Ethinyl Estradiol | 1 | 1990 | 2 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 1990 | 3 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1990 | 7 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 1990 | 74 | 0.020 |
Why?
|
| Cognitive Dysfunction | 1 | 2020 | 998 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 193 | 0.020 |
Why?
|
| Sex Factors | 1 | 1990 | 429 | 0.020 |
Why?
|
| Receptors, Glutamate | 1 | 1995 | 2 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 1995 | 25 | 0.010 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 1995 | 26 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1995 | 467 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1992 | 249 | 0.010 |
Why?
|